




## Background

Amura Therapeutics Limited is a drug discovery business specialising in the development of inhibitors of CAC1 cysteine peptidases. Cysteine peptidases are involved in several commercial and therapeutically important diseases such as **osteoporosis, bone metastasis, osteoarthritis, rheumatoid arthritis, multiple sclerosis, atherosclerosis, chronic pain** and **malaria**. Amura's compounds are derived from the proprietary **AMcore™** scaffold, which provides a turnkey solution for inhibitor design against cysteine peptidases of the CAC1 family. Amura has discovered novel chemical entities (NCE's) that are readily synthesised and exhibit excellent *in vitro* activity, primary DMPK stability, rodent and non-human primate oral pharmacokinetics, safety pharmacology, functional cell-based activity and efficacy in *in vivo* disease related animal models. Amura intends to out-license its programmes for clinical development.



## Cathepsin K Inhibitors

Amura's **AMcore™** derived inhibitors have proven efficacious in a variety of industry gold standard animal models targeting blockbuster therapeutic indications. All compounds tested are via oral administration and key highlights include:-

### Osteoporosis

- In a non-human primate study, multiple compounds significantly reduced serum bone markers (sCTXI and sNTx); improving upon the profile of competitor compounds that have entered the clinic. The pharmacodynamic effect is maintained for many hours upon single oral dose.
- In an ovariectomized rat model of osteoporosis, multiple compounds demonstrated a dose dependant and significant decrease in serum bone markers (sCTXI) As a result, turnover index (sCTXI/osteocalcin) was significantly decreased by all six test compounds.
- Compounds show excellent pharmacokinetic profiles, safety pharmacology and toxicity profile.

### Bone metastasis

- In a human breast cancer cell-induced mouse model of bone metastasis, compound demonstrated a reduction in lesion size and total tumour burden associated with metastasis compared to the control group.
- Compounds show excellent pharmacokinetic profiles, safety pharmacology and toxicity profile.

### Osteoarthritis

- In a rat surgical menisectomy model of osteoarthritis, compound showed significant beneficial effects on tibial cartilage degeneration and total joint score compared to the control group.
- Additionally, compound demonstrated a significant decrease in synovial fluid collagen markers (CTxI and CTxII) in a rat surgical menisectomy model.
- Compounds show excellent pharmacokinetic profiles, safety pharmacology and toxicity profile.



## SENIOR MANAGEMENT

**Dr. David Brown**  
Chairman

**Dr Martin Quibell**  
Chief Scientific Officer

**Dr Daniel Roach**  
General Manager

Amura Holdings Ltd.  
Building 405  
Babraham Research Campus  
Babraham  
Cambridgeshire  
CB22 3AT  
United Kingdom

☎ +44(0)1223 839797  
☎ +44(0)1223 839898  
✉ amura@amura.co.uk  
🌐 www.amura.co.uk



## Cathepsin S Inhibitors

Amura's **AMcore™** derived inhibitors have proven efficacious in a variety of industry gold standard animal models targeting blockbuster therapeutic indications. All compounds tested are via oral administration and key highlights include:-

### Rheumatoid arthritis


- In a collagen-induced arthritis animal model, compound demonstrated a marked reduction in collagen-specific antibodies.
- Additionally, a significant decrease in joint swelling score was observed, along with a significant improvement in joint histopathology.
- Compounds show excellent pharmacokinetic profiles, safety pharmacology and toxicity profile.

### Chronic neuropathic pain

- In a rat sciatic nerve ligature model, multiple compounds demonstrated a rapid and marked inhibition of mechanical hyperalgesia.
- Inhibition was dose-dependant and fully reversible.
- Compounds show excellent pharmacokinetic profiles, safety pharmacology and toxicity profile.

### AMcore™ intellectual property

The key proprietary **AMcore™** bicyclic scaffolds are:



Patent number	Normal expiry	AU	BR	CA	CN	EU	HK	IN	ID	IL	JP	KR	MX	NZ	NO	PH	RU	SA	SG	UA	US	
WO02057270	01-22	G	U	U	G	G	G	G	G	G	U	G	G	G	P	P	G	G	G	G	G	G
		P	U		G																	
		2001	2002	2003	2004	2005	2006	2007	2008		Exp. date											
WO02057248	Cysteine protease inhibitor										01-2021											
WO02057270	Cysteine protease inhibitor										01-2021											
WO02057246	Cysteine protease inhibitor										01-2021											
WO02057249	Cysteine protease inhibitor										01-2021											
WO04007501	Cysteine protease inhibitor										07-2022											
WO07017698	AMcore™ Process1										08-2025											
WO07023281	Mimetics										08-2025											
WO08007132	AMcore™ Process2										07-2026											
WO08007109	Selection										07-2026											
WO08007103	Selection										07-2026											
WO08007130	Selection										07-2026											
WO08007114	Selection										07-2026											
WO08007127	Selection										07-2026											
WO08007107	Selection										07-2026											
WO09087379	Selection										01-2028											
GB0804701.1	Selection										03-2028											
GB0804792.9	Selection										03-2028											
GB0809776.8	Selection										05-2028											

The granted patents protect the use of **AMcore™** derived 5,5-bicyclic ketones as inhibitors of CAC1 cysteine peptidases to provide new medicines for diseases such as **osteoporosis, bone metastasis, osteoarthritis, rheumatoid arthritis, chronic pain and malaria.**

Amura intends to out-license/partner its programmes for clinical development.



## AMURA INVESTORS

### Avlar BioVentures

☎ +44(0)1954 211 515  
 ☎ +44(0)1223 211 516  
 ✉ avlar@avlar.com  
 🌐 www.avlar.com

### Noble Group

☎ +44(0)20 7763 2200  
 ☎ +44(0)20 7763 2399  
 ✉ noble@noblegp.com  
 🌐 www.noblegp.com

## LICENSING OPPORTUNITIES

### Dr. David Brown

☎ +44(0)1223 839797  
 ☎ +44(0)1223 839898  
 ✉ david.brown@amura.co.uk  
 🌐 www.amura.co.uk